GlassScriptPhysician profile
Brian M Braithwaite
NPI 1518020072
$12,156.99
in general payments reported to CMS, 2019-2025
8 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $239 · 2021: $53.11 · 2022: $211 · 2023: $381 · 2024: $55.29 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,336.75 | 2019-2020 | |
| Merz North America, INC. | $525.41 | 2019-2023 | Xeomin |
| Mentor Worldwide LLC | $415.80 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Abbott Laboratories | $409.63 | 2022-2023 | Proclaim |
| Galderma Laboratories, L.P. | $306.57 | 2019-2025 | Dysport |
| Medtronic, INC. | $75.52 | 2025 | Inceptiv |
| Motiva USA, LLC | $53.23 | 2025 | |
| Integra Lifesciences Corporation | $34.08 | 2025 | Integra, Surgimend, Omnigraft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Braithwaite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.